Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma

Canine transitional cell carcinoma (cTCC) is the most common naturally occurring bladder cancer and accounts for 1–2% of canine tumors. The prognosis is poor due to the high rate of invasiveness and metastasis at diagnosis. Sorafenib is a multi-kinase inhibitor that targets rapidly accelerated fibro...

Descripción completa

Detalles Bibliográficos
Autores principales: YOKOTA, Shohei, YONEZAWA, Tomohiro, MOMOI, Yasuyuki, MAEDA, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177404/
https://www.ncbi.nlm.nih.gov/pubmed/35387955
http://dx.doi.org/10.1292/jvms.21-0478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177404/
https://www.ncbi.nlm.nih.gov/pubmed/35387955
http://dx.doi.org/10.1292/jvms.21-0478

Ejemplares similares